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Background/Aim: Oedema is a common and serious side effect of thiazolidinedione 
therapy. A stratified medicine approach would aim to give thiazolidinediones to patients likely 
to have a good glycaemic response but to not develop oedema.  We investigated whether 
oedema was associated with glycaemic response to thiazolidinedione therapy. 
Methods: We studied 10,486 patients initiating a thiazolidinedione from Clinical Practice 
Research Datalink (CPRD), and identified medical records of oedema in the subsequent 
twelve months. Response was defined as change in HbA1c at twelve months and was 
adjusted for baseline HbA1c, baseline BMI, gender and adherence (medication possession 
ratio). In secondary analyses we restricted oedema classification to patients with 
concomitant weight gain. As a comparison the same analysis was performed in 13,089 
patients initiating a sulfonylurea.  
Results: The 3% of patients with recorded oedema on thiazolidinediones had a mean (CI) 3 
(1.7-4.3)mmol/mol greater fall in HbA1c (p<0.001) compared to those without oedema. This 
improved response increased when oedema was associated with weight gain, with a 4.1 
(1.9-6.2)mmol/mol greater HbA1c fall when weight gain >3kg (p<0.001) and a 5.2 (2.1-
8.4)mmol/mol greater fall when weight gain >8kg (p<0.001). In sulfonylurea patients oedema 
was not associated with response (HbA1c fall difference 1 (-0.5-2.5)mmol/mol, p=0.2), even 
when associated with weight gain >3kg (p=0.19). 
Conclusion: Patients with Type 2 diabetes who develop oedema on initiating 
thiazolidinediones have an improved glycaemic response, and more severe oedema is 
associated with greater HbA1c reduction. This supports glycaemic lowering and fluid 
retention being mediated by a common pathway of thiazolidinedione drug action.  
 
 
